ArticleClinical research in cardiology : official journal of the German Cardiac Society2020
Residual inflammatory risk in coronary heart disease: incidence of elevated high-sensitive CRP in a real-world cohort.
Article in Clinical research in cardiology : official journal of the German Cardiac Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 3 syntheses or guidelines pooled it, 62 citations in OpenAlex.
- Association between microRNA-146a rs2910164 polymorphism and coronary heart disease: An updated meta-analysis.Medicine · 2022Pooled it
- Inflammatory bowel disease and risk of coronary heart disease : A Mendelian randomization study.Wiener klinische Wochenschrift · 2022Pooled it
- The impact of SSRIs on mortality and cardiovascular events in patients with coronary artery disease and depression: systematic review and meta-analysis.Clinical research in cardiology : official journal of the German Cardiac Society · 2021Pooled it
- Predictive factors and pharmacological preventive interventions for atrial fibrillation after aortic valve replacement.Journal of cardiothoracic surgery · 2025Trial
- The effect of multistrain probiotics on functional constipation in the elderly: a randomized controlled trial.European journal of clinical nutrition · 2022Trial
- Atherosclerotic Cardiovascular Disease and Cancer.Immunological reviews · 2026Review
- Prevalence and characteristics of adults with atherosclerotic cardiovascular disease, chronic kidney disease, and systemic inflammation in the USA.American heart journal plus : cardiology research and practice · 2026Article
- Urine color tool for coronary heart disease phenotyping.Scientific reports · 2025Article
- Residual Inflammatory and Cholesterol Risk and the Association With Recurrent Cardiovascular Events in East Asian Patients After Percutaneous Coronary Intervention.Reviews in cardiovascular medicine · 2025Article
- Perceptions of high-sensitivity C-reactive protein testing (hsCRP) in atherosclerotic cardiovascular disease: a US survey on cardiologists and nephrologists.Future cardiology · 2025Article
- High prevalence of low vitamin D status in the Czech Republic: a retrospective study of 119,925 participants.European journal of clinical nutrition · 2025Article
- Expression level and clinical significance of IL-29 in serum of patients with coronary heart disease.Journal of cardiothoracic surgery · 2025Article
- The Role of High-SensitivityNutrients · 2025Article
- Impact of NSAIDs corticosteroids DMARDs biologics and their comparisons with natural products in C-reactive proteins (CRP) linked cardiovascular disorders.Inflammopharmacology · 2025Review
- Prevalence and clinical characteristics of patients with hsCRP testing and test-confirmed systemic inflammation among individuals with atherosclerotic cardiovascular disease with or without chronic kidney disease in the United States (PLUTUS).American journal of preventive cardiology · 2025Article
- Remnant Cholesterol Inflammatory Index for Predicting Heart Failure Risk in Patients with Coronary Artery Disease and Type 2 Diabetes: A Retrospective Study Using Multiple Machine Learning Approaches.Risk management and healthcare policy · 2025Article
- Combining triglyceride glucose-body mass index and high-sensitivity C-reactive protein to predict cardiovascular disease: results from a national cohort and a clinical verified cohort.Frontiers in cardiovascular medicine · 2025Article
- Methylation patterns associated with C-reactive protein in racially and ethnically diverse populations.Epigenetics · 2024Article
- Systemic inflammation and health outcomes in patients receiving treatment for atherosclerotic cardiovascular disease.European heart journal · 2024Observational
- Novel and Emerging LDL-C Lowering Strategies: A New Era of Dyslipidemia Management.Journal of clinical medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInflammation drives atherosclerosis and its complications. Anti-inflammatory therapy with interleukin 1 beta (IL-1β) antibody reduces cardiovascular events in patients with elevated high-sensitive C-reactive protein (hsCRP). This study aims to identify the share of patients with coronary heart disease (CHD) and residual inflammation who may benefit from anti-inflammatory therapy.
methodshsCRP and low-density lipoprotein (LDL) levels were determined in 2741 all-comers admitted to the cardiological ward of our tertiary referral hospital between June 2016 and June 2018. Patients without CHD, with acute coronary syndrome, chronic or recurrent systemic infection, use of immunosuppressant or anti-inflammatory agents, chronic inflammatory diseases, chemotherapy, terminal organ failure, traumatic injury and pregnancy were excluded.
results856 patients with stable CHD were included. 42.7% of those had elevated hsCRP ≥ 2 mg/l. Within the group of patients with LDL-cholesterol < 70 mg/dl, 30.9% shared increased hsCRP indicating residual inflammation. After multivariate adjusted backward selection elevated Lipoprotein (a) (OR 1.61, p = 0.048), elevated proBNP (OR 2.57, p < 0.0001), smoking (OR 1.70, p = 0.022), and obesity (OR 2.28, p = 0.007) were associated with elevated hsCRP. In contrast, the use of ezetimibe was associated with normal hsCRP (OR 0.51, p = 0.014). In the subgroup of patients with on-target LDL-cholesterol < 70 mg/dl, backward selection identified elevated proBNP (OR 3.49, p = 0.007) as independent predictor of elevated hsCRP in patients with LDL-cholesterol < 70 mg/dl.
conclusionOne-third of all-comers patients with CHD showed increased levels of hsCRP despite a LDL-cholesterol < 70 mg/dl potentially qualifying for an anti-inflammatory therapy. Elevated proBNP is an independent risk factor for hsCRP elevation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.